HIV/AIDS Therapy
Panacos announces first cohort results of Phase IIb study of bevirimat
Published in AIDS Weekly, January 15th, 2007
The data confirm the clinical antiviral activity of bevirimat shown in previous studies; however, the bevirimat plasma concentrations were lower than anticipated, suggesting that the tablet formulation used for this study did not deliver the drug as expected.
After 14 days of dosing with 400 mg of bevirimat tablets administered on top of patients' failing background regimens, an antiviral effect was seen in the bevirimat treatment group. Two out of twelve patients...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2007-01-15)
More Articles from AIDS Weekly
- HIV/AIDS Research
HIV treatments improve health, but nutritional issues remain - HIV/AIDS
Findings from Institute of Microbiology and Epidemiology advance knowledge in HIV/AIDS - HIV/AIDS
New HIV/AIDS in children research has been reported by scientists at Johns Hopkins Medical Institutions, Division of General Pediatrics - HIV/AIDS Cancer Therapy
New findings from University of Wisconsin in the area of HIV/AIDS cancer therapy published - HIV/AIDS Co-Infection Genetics
Data on HIV/AIDS co-infection genetics published by researchers at Drexel University - HIV/AIDS Co-Infection Immunology
Research from University of California, Divisions of Cardiology in HIV/AIDS co-infection immunology provides new insights - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
